Evidence map›Paper›PMID 26000830›Full record

SynthesisPloS one2015

Efficacy of deferoxamine in animal models of intracerebral hemorrhage: a systematic review and stratified meta-analysis.

Han-Jin Cui, Hao-yu He, A-Li Yang, Hua-Jun Zhou, Cong Wang, Jie-Kun Luo, Yuan Lin, Tao Tang

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 6 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 6 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Efficacy of desferrioxamine mesylate in intracerebral hematoma: a systemic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Review
  10. Review
  11. Therapeutic potential of iron chelators in retinal vascular diseases.International journal of ophthalmology · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Han-Jin CuiInstitute of Integrative Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Institute of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Hao-yu HeInstitute of Mental Health, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
A-Li YangInstitute of Neurology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Key Lab of Chinese Gan of SATCM, Changsha, 410008, Hunan, China.
Hua-Jun ZhouKey Lab of Chinese Gan of SATCM, Changsha, 410008, Hunan, China; Institute of Neurology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang, 443003, Hubei, China.
Cong WangInstitute of Integrative Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Key Lab of Chinese Gan of SATCM, Changsha, 410008, Hunan, China.
Jie-Kun LuoInstitute of Integrative Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Key Lab of Chinese Gan of SATCM, Changsha, 410008, Hunan, China.
Yuan LinKey Lab of Chinese Gan of SATCM, Changsha, 410008, Hunan, China.
Tao TangInstitute of Integrative Medicine, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China; Key Lab of Chinese Gan of SATCM, Changsha, 410008, Hunan, China.
Xiangya Hospital Central South University · CNCentral South University · CNChina Three Gorges University · CNSecond Xiangya Hospital of Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intracerebral hemorrhage (ICH) is a subtype of stroke associated with high morbidity and mortality rates. No proven treatments are available for this condition. Iron-mediated free radical injury is associated with secondary damage following ICH. Deferoxamine (DFX), a ferric-iron chelator, is a candidate drug for the treatment of ICH. We performed a systematic review of studies involving the administration of DFX following ICH. In total, 20 studies were identified that described the efficacy of DFX in animal models of ICH and assessed changes in the brain water content, neurobehavioral score, or both. DFX reduced the brain water content by 85.7% in animal models of ICH (-0.86, 95% CI: -.48- -0.23; P < 0.01; 23 comparisons), and improved the neurobehavioral score by -1.08 (95% CI: -1.23- -0.92; P < 0.01; 62 comparisons). DFX was most efficacious when administered 2-4 h after ICH at a dose of 10-50 mg/kg depending on species, and this beneficial effect remained for up to 24 h postinjury. The efficacy was higher with phenobarbital anesthesia, intramuscular injection, and lysed erythrocyte infusion, and in Fischer 344 rats or aged animals. Overall, although DFX was found to be effective in experimental ICH, additional confirmation is needed due to possible publication bias, poor study quality, and the limited number of studies conducting clinical trials.

Indexed as

AnimalsCerebral HemorrhageDeferoxamineDisease Models, AnimalMiceRatsSiderophoresSwineTreatment OutcomeDeferoxamineSiderophores

Identifiers

PMID26000830
PMCPMC4441464
OpenAlexW1508884137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.